Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 19/20 | 0.42 |
| ▸ | CDK9 | P50750 | 19/20 | 0.42 |
| ▸ | CDK4 | P11802 | 18/20 | 0.42 |
| ▸ | CCND1 | P24385 | 18/20 | 0.42 |
| ▸ | CDK2 | P24941 | 12/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30603622 | 1.00 | CCND3 (0.42) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL30603698 | 0.81 | CDK9 (0.54) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL26127062 | 0.81 | CDK9 (0.54) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL19836340 | 0.80 | GRM5 (0.35) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL30603673 | 0.79 | CDK9 (0.39) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL26126669 | 0.79 | CDK9 (0.39) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL26585395 | 0.78 | CCNT1 (0.57) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL30589198 | 0.75 | CCNT1 (0.47) | CCNT1CDK9CDK4CCND1CDK2 | |
| SCHEMBL31562926 | 0.75 | CCNT1 (0.53) | CCND3CDK6CCNT1CDK9CDK4 | |
| SCHEMBL27214077 | 0.75 | CCNT1 (0.53) | CCND3CDK6CCNT1CDK9CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150322-A1 | CDK9 Inhibitors | BAERENKRAFT THERAPEUTICS, LLC | 2024-05-09 | — | — | US | disclosed |
| WO-2023196518-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196518-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150322-A1 | CDK9 Inhibitors | CDK9, CDK19, CDK1 | CCND3 62/4885CDK6 14/4885CCNT1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.